Dong-Hoe Koo , MD, PhD 1 , 2 , Min-Hee Ryu , MD, PhD 2 , 3 , Kyoung-Mee Kim , MD, PhD 2 , 4 , Han-Kwang Yang , MD, PhD 2 , 5 , Akira Sawaki , MD, PhD 6 , 7 , Seiichi Hirota , MD, PhD 7 , 8 , Jie Zheng , MD, PhD 9 , 10 , Bo Zhang , MD, PhD 10 , 11 , Chin-Yuan Tzen , MD, PhD 12 , Chun-Nan Yeh , MD 13 , Toshirou Nishida , MD, PhD 7 , 14 , Lin Shen , MD, PhD 10 , 15 , Li-Tzong Chen , MD, PhD 16 , 17 , Yoon-Koo Kang , MD, PhD 2 , 3
24 June 2016
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors originating in the gastrointestinal tract. With the introduction of molecular-targeted therapy for GISTs which has yielded remarkable outcomes, these tumors have become a model of multidisciplinary oncological treatment. Although Western clinical guidelines are available for GISTs, such as those published by the National Comprehensive Cancer Network (NCCN) and the European Society of Medical Oncology (ESMO), the clinical situations in Asian countries are different from those in Western countries in terms of diagnostic methods, surgical approach, and availability of new targeted agents. Accordingly, we have reviewed current versions of several GIST guidelines published by Asian countries (Japan, Korea, China, and Taiwan) and the NCCN and ESMO and discussed the areas of dissensus. We here present the first version of the Asian GIST consensus guidelines that were prepared through a series of meetings involving multidisciplinary experts in the four countries. These guidelines provide an optimal approach to the diagnosis and management of GIST patients in Asian countries.